These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21242023)

  • 1. Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy.
    Tug N; Uslu U; Cumbul A; Eyuboglu S; Cam C; Karateke A; Yilmaz B
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):166-70. PubMed ID: 21242023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-induced delayed ovulation affects early embryonic development.
    Bittner AK; Horsthemke B; Winterhager E; Grümmer R
    Fertil Steril; 2011 Jun; 95(7):2390-4. PubMed ID: 21474126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis.
    Altintas D; Kokcu A; Tosun M; Cetinkaya MB; Kandemir B
    J Obstet Gynaecol Res; 2008 Dec; 34(6):1014-9. PubMed ID: 19012701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary.
    Collado B; Carmena MJ; Cortés J; Schally AV; Prieto JC
    Int J Oncol; 2004 Mar; 24(3):725-30. PubMed ID: 14767559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
    Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
    Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats.
    Zhao XJ; Huang YH; Yu YC; Xin XY
    Gynecol Oncol; 2010 Jul; 118(1):69-75. PubMed ID: 20417958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study.
    Olivennes F; Fanchin R; Bouchard P; Taïeb J; Selva J; Frydman R
    Hum Reprod; 1995 Jun; 10(6):1382-6. PubMed ID: 7593501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle.
    Evans MJ; Alexander SL; Irvine CH; Kitson NE; Taylor TB
    Anim Reprod Sci; 2011 Sep; 127(3-4):188-96. PubMed ID: 21889856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.
    Büchter D; Behre HM; Kliesch S; Chirazi A; Nieschlag E; Assmann G; von Eckardstein A
    Exp Clin Endocrinol Diabetes; 1999; 107(8):522-9. PubMed ID: 10612483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study.
    Engel JB; Audebert A; Frydman R; Zivny J; Diedrich K
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):225-32. PubMed ID: 16930803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.